The first dosage of its plasmid DNA vaccine ZyCoV-D was administered to a human test subject on Wednesday, the company said in a statement.
The company said the DNA vaccine platform it had developed could be used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.